RxDoctor Payments Data

Mark Quiring, MD

Family Medicine · Mount Pleasant, TXNPI 1356343412

Payments from drug & device makers

$2,149in general payments, 2019–2025

Across 45 payments — averaging $47.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$603
  • Boston Scientific$500
  • Calyxo, Inc.$195
  • Johnson & Johnson$152
  • GSK$125
  • Amgen$96
  • plus $478 from 13 others

What the payments were for

  • Speaking & faculty fees$60328%
  • Food & beverage$1,52171%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,149 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$118,455
Medicare patients
203
Services billed
3,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide146$193,294
RybelsusSemaglutide55$79,023
EliquisApixaban76$68,343
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$64,213
MounjaroTirzepatide30$49,306
Tresiba Flextouch U-200Insulin Degludec48$34,792
JardianceEmpagliflozin22$29,274
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog56$28,592
MyrbetriqMirabegron18$17,328
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$10,183
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$8,266
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm28$6,143
BelsomraSuvorexant12$5,469
Tresiba Flextouch U-100Insulin Degludec14$4,534
Albuterol Sulfate HfaAlbuterol Sulfate167$4,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$48$272,316201 claims
PfizerEliquis$23$68,34376 claims
GSKTrelegy Ellipta$125$64,21372 claims
Boehringer IngelheimJardiance, Stiolto Respimat$17$37,54040 claims
AbbVieSynthroid$17$1,39528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Mount Pleasant

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →